{"id":"NCT02698475","sponsor":"Janssen Research & Development, LLC","briefTitle":"An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age","officialTitle":"A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05","primaryCompletion":"2017-12","completion":"2020-10","firstPosted":"2016-03-03","resultsPosted":"2020-08-28","lastUpdate":"2021-11-01"},"enrollment":44,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Ustekinumab 0.75 mg/kg","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 45 mg","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 90 mg","otherNames":[]}],"arms":[{"label":"Ustekinumab Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (\\>=) 6 through less than (\\<) 12 years with moderate to severe chronic plaque psoriasis","primaryOutcome":{"measure":"Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Ustekinumab Standard Dose (Main Study)","deltaMin":77.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":31,"countries":["United States","Belgium","Canada","Germany","Hungary","Netherlands","Poland","South Korea","Taiwan"]},"refs":{"pmids":["36171515"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":44},"commonTop":["Nasopharyngitis","Injection Site Erythema","Upper Respiratory Tract Infection","Pharyngitis","Gastroenteritis"]}}